Home » Stocks » ILMN

Illumina, Inc. (ILMN)

Stock Price: $451.96 USD 0.15 (0.03%)
Updated Jun 16, 2021 10:27 AM EDT - Market open
Market Cap 65.50B
Revenue (ttm) 3.47B
Net Income (ttm) 630.00M
Shares Out 146.00M
EPS (ttm) 4.28
PE Ratio 105.60
Forward PE 80.65
Dividend n/a
Dividend Yield n/a
Trading Day June 16
Last Price $451.96
Previous Close $451.81
Change ($) 0.15
Change (%) 0.03%
Day's Open 454.21
Day's Range 447.50 - 457.20
Day's Volume 73,208
52-Week Range 260.42 - 555.77

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Cathie Wood lost her conviction and dumped the stock. Can Illumina get back on track?

4 days ago - The Motley Fool

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--The DNA Data Storage Alliance, an organization of more than 25 leading companies formed by Twist Bioscience Corporation (NASDAQ: TWST), Illumina, Inc. (NASD...

Other stocks mentioned: TWST, WDC
6 days ago - Business Wire

It'll cover a lot of ground in the next 14 years.

1 week ago - The Motley Fool

These healthcare stocks are at the forefront of huge trends, including precision medicine and advances in diagnosis technologies. The post 5 Healthcare Stocks to Buy for Their Game-Changing Potential ap...

Other stocks mentioned: BNGO, MRNA, NVTA, SDGR
1 week ago - InvestorPlace

Are you looking for stocks that have been beaten up in recent weeks? Here are seven stocks to buy right now at the start of the summer.

Other stocks mentioned: ADBE, AZN, BIIB, DPZ, ORLY, VZ
1 week ago - InvestorPlace

Illumina's (ILMN) VeriSeq NIPT Solution v2 provides accurate, consistent and scalable end-to-end genome-wide noninvasive prenatal testing.

2 weeks ago - Zacks Investment Research

SAN DIEGO--(BUSINESS WIRE)--Illumina and BeSolveRD will study the clinical utility and health economic impact of WGS of patients with intellectual disabilities.

2 weeks ago - Business Wire

MELBOURNE, Australia--(BUSINESS WIRE)--Illumina and Next Generation Genomic Co. announced launch of VeriSeq™ NIPT Solution v2 in Thailand, a CE-IVD, NGS-based approach to NIPT.

2 weeks ago - Business Wire

SAN DIEGO--(BUSINESS WIRE)---- $ILMN #ILMN--Illumina, Inc. (NASDAQ: ILMN) today announced that its executives will be speaking at the following investor conference: Goldman Sachs 42nd Annual Global Heal...

2 weeks ago - Business Wire

Illumina (ILMN) reported earnings 30 days ago. What's next for the stock?

2 weeks ago - Zacks Investment Research

Is (ILMN) Outperforming Other Medical Stocks This Year?

3 weeks ago - Zacks Investment Research

Guardant Health released earnings earlier this month, disappointing investors with its sluggish revenue growth and increasing expenses.

Other stocks mentioned: ARKG, GH, RHHBY
3 weeks ago - The Motley Fool

10x Genomics stock has fallen, despite announcing strong first-quarter numbers.

Other stocks mentioned: NSTG, TXG
3 weeks ago - The Motley Fool

We have narrowed down our search to five S&P 500 stocks that have attained a 52-week high this year but are currently trading at a deep discount. These are: MAR, PHM, WY, GM and ILMN.

Other stocks mentioned: GM, MAR, PHM, WY
4 weeks ago - Zacks Investment Research

Several executives who earned their spurs at dominant genetics sequencing company Illumina Inc. ( ILMN , Financial) hold key management positions at a firm that is planning a $100 million initial public...

4 weeks ago - GuruFocus

SAN DIEGO--(BUSINESS WIRE)--Illumina appoints Susan Tousi as Chief Commercial Officer and Dr. Alex Aravanis as Chief Technology Officer, Head of Research and Product Development

4 weeks ago - Business Wire

Investors continue to be optimistic about Illumina (ILMN), backed by its focus on partnerships and robust adoption of its products.

1 month ago - Zacks Investment Research

Despite a Q1 beat, Illumina has seen its share price decline over the last week (five trading sessions). The only negative from the earnings announcement was the margin contraction.

1 month ago - Forbes

Twist Bioscience brings to mind another genomic revolution pioneer.

Other stocks mentioned: ARKG, TWST
1 month ago - The Motley Fool

It just might be.

1 month ago - The Motley Fool

The advice of Warren Buffett's biggest influencers supports these solid picks.

Other stocks mentioned: ISRG
1 month ago - The Motley Fool

SAN DIEGO--(BUSINESS WIRE)---- $ILMN #ILMN--Illumina, Inc. (NASDAQ: ILMN) today announced that its executives will be speaking at the following investor conference: Bank of America 2021 Healthcare Confe...

1 month ago - Business Wire

SAN DIEGO--(BUSINESS WIRE)--Illumina, Inc. (NASDAQ: ILMN) announced today that it has filed an action in the General Court of the European Union asking for annulment of the European Commission's decisio...

1 month ago - Business Wire

Illumina (ILMN) exhibits an impressive performance by its Instruments segment in the first quarter of 2021 despite pandemic-led business disruptions.

1 month ago - Zacks Investment Research

SAN DIEGO--(BUSINESS WIRE)--Illumina announced commitment of $60 million to a global pathogen genomics initiative, in partnership with the Bill & Melinda Gates Foundation.

1 month ago - Business Wire

Nearly everything went right for the genomic sequencing pioneer.

1 month ago - The Motley Fool

Illumina (ILMN) delivered earnings and revenue surprises of 38.97% and 0.74%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

SAN DIEGO--(BUSINESS WIRE)---- $ILMN #ILMN--Illumina, Inc. (NASDAQ: ILMN) today announced its financial results for the first quarter of fiscal year 2021. First quarter results reflect record revenue: R...

1 month ago - Business Wire

Illumina (ILMN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

1 month ago - Zacks Investment Research

The government is going to invest heavily in COVID-19 research and tracking, and these companies are likely to benefit.

Other stocks mentioned: FLGT, TXG
1 month ago - The Motley Fool

Illumina Inc (NASDAQ: ILMN) and privately-held Kartos Therapeutics have announced a partnership to develop a next-generation sequencing-based TP53 companion diagnostic. The diagnostic will be based on I...

1 month ago - Benzinga

SAN DIEGO--(BUSINESS WIRE)--Illumina and Kartos Therapeutics announce a new partnership to co-develop a TP53 CDx based on the TruSight™ Oncology 500 (TSO 500) assay.

1 month ago - Business Wire

Illumina (ILMN) is likely to have gained during the first quarter on the back of robust performance of the sequencing consumable segment.

1 month ago - Zacks Investment Research

SAN DIEGO--(BUSINESS WIRE)--Illumina disagrees with the European Commission's Directorate-General for Competition's decision to review Illumina's acquisition of GRAIL.

1 month ago - Business Wire

The administration's focus on the Affordable Care Act, access to healthcare, and research may accelerate growth for these three stocks.

Other stocks mentioned: OSCR, TDOC
1 month ago - The Motley Fool

Sometimes the most carefully laid plans hit unforeseen snags.

2 months ago - The Motley Fool

The gene sequencing giant has a couple of key challenges going forward.

2 months ago - The Motley Fool

SINGAPORE--(BUSINESS WIRE)--Illumina Named One of Singapore's Best Employers

2 months ago - Business Wire

SINGAPORE--(BUSINESS WIRE)--Illumina Named One of Singapore's Best Employers

2 months ago - Business Wire

Illumina (ILMN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

2 months ago - Zacks Investment Research

Regulatory and drug-pricing worries have knocked biotech stocks off their Covid-19 pedestal. After hitting a high point in early February, biotech stocks have collectedly fallen 21%.

Other stocks mentioned: ABBV, ACAD, ALXN, AZN, BIIB, BNTX, CRSP ...
2 months ago - Investors Business Daily

This giant of the genomic revolution ticks nearly all the boxes dividend investors should look for.

2 months ago - The Motley Fool

The chances are certainly higher now that the deal won't happen.

2 months ago - The Motley Fool

The chief executive of life sciences company Illumina argued Thursday his company's deal to buy back GRAIL would lead to cheaper cancer tests rather than potentially pushing up prices as the government ...

2 months ago - Reuters

The biotech was under pressure last month, but it's bouncing back in April.

2 months ago - The Motley Fool

The DNA sequencing company is gearing up to report a big beat later this month.

2 months ago - The Motley Fool

Illumina's (ILMN) revenue improvement in the first quarter is likely to have been boosted by on-going business recovery.

2 months ago - Zacks Investment Research

Illumina stock gapped up Tuesday after the company preannounced 26% revenue growth in the first quarter and boosted its full-year guidance. Analysts were split on the preannouncement.

2 months ago - Investors Business Daily

The shares of Illumina Inc (NASDAQ:ILMN) are surging today, up 9.2% to trade at $420 at last check, after the company announced better-than-expected preliminary current-quarter and full-year guidance.

2 months ago - Schaeffers Research

Illumina CEO Francis deSouza on first-quarter results, outlook and more

YouTube video

Illumina issued preliminary current-quarter and full-year guidance that exceeded current analyst estimates. The life sciences company said its projected results are being driven by record orders in its ...

2 months ago - CNBC Television

About ILMN

Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements. Its customers i... [Read more...]

Industry
Diagnostics & Research
IPO Date
Jul 28, 2000
CEO
Jay Flatley
Employees
7,800
Stock Exchange
NASDAQ
Ticker Symbol
ILMN
Full Company Profile

Financial Performance

In 2020, Illumina's revenue was $3.24 billion, a decrease of -8.58% compared to the previous year's $3.54 billion. Earnings were $656.00 million, a decrease of -34.53%.

Financial Statements

Analyst Forecasts

According to 18 analysts, the average rating for Illumina stock is "Hold." The 12-month stock price forecast is 410.18, which is a decrease of -9.24% from the latest price.

Price Target
$410.18
(-9.24% downside)
Analyst Consensus: Hold